Home hyperbaric chamber safety: what the research actually shows
A 1.3 ATA home chamber is not clinical hyperbaric oxygen therapy, and the difference matters for safety. This guide grades the real risks and side effects, from ear barotrauma to oxygen-toxicity seizures to fire, against the primary research, and is honest about where the evidence does not reach.
Published August 21, 2026
Not medical advice. Talk to a qualified clinician before starting any new health protocol, especially if you take medication or have a medical condition.
16 minutes
HBOT risks and home-chamber safety
The bottom line
Clinical hyperbaric oxygen therapy is genuinely low-risk when used for FDA-cleared indications at a monitored facility. Serious complications are rare. The risks that get the headlines, oxygen-toxicity seizures and fire, are either rare or tied to high pressure and unsupervised oxygen use.
A home 1.3 ATA chamber is a different situation. It runs at lower pressure with filtered room air, so the per-session risk of oxygen toxicity and barotrauma is lower. But there is no large safety trial of home chambers specifically, and the sessions are unsupervised. Lower pressure is not zero risk, and a less-studied dose is not a proven-safe dose.
The real safety controls are not the ATA number. They are a prescription and screening, a verifiable FDA clearance, a trained second adult outside the chamber, and strict fire and oxygen rules.
What the evidence actually says
These are editorial grades based on the peer-reviewed literature and official bodies. A grade is not a medical recommendation, and no grade removes the need for screening. The honest pattern: the common complications are ear barotrauma and temporary vision change, the rare one is oxygen-toxicity seizure, and the catastrophic one is fire.
| Claim | Grade | What the evidence says |
|---|---|---|
| HBOT is generally safe when used for FDA-cleared indications | Strong | The FDA states HBOT is generally safe and serious complications are rare for cleared uses at accredited facilities. The risk profile changes when a chamber is unreviewed, unaccredited, or used for unproven conditions. |
| Untreated pneumothorax is an absolute contraindication | Strong | StatPearls identifies an untreated pneumothorax as the only absolute contraindication. Changing pressure can convert it into a life-threatening tension pneumothorax during ascent, so screening is not optional. |
| Ear and sinus barotrauma is the most common complication | Strong | The FDA lists ear and sinus pain and middle-ear injuries as HBOT risks. Studies report middle-ear barotrauma in roughly 13% to 43% of patients, with the vast majority being minor. Incidence varies with population and definition. |
| HBOT causes a temporary myopic shift that recovers | Strong | Evanger 2004 found a significant reversible near-sighted shift, larger with hood delivery than with a mask, that returned to baseline within 6 to 10 weeks. No significant lens damage was seen in that study. |
| Oxygen-toxicity seizures are rare and pressure-dependent | Strong | Heyboer 2014 measured roughly 5 seizures per 10,000 treatments overall, with zero at 2.0 ATA and 51 per 10,000 at 2.8 ATA. Hampson 2003 found about 1 in 3,388 treatments. Risk rises with pressure. |
| Serial HBOT does not reliably damage standard lung function | Moderate | Brenna 2023 followed patients through serial sessions and found no significant longitudinal change in FEV1, FVC, or FEF25-75, even with pre-existing respiratory disease. This is observational, not an RCT. |
| Fire is the catastrophic risk, documented in unreviewed chambers | Strong | The FDA has documented explosions and fires in chambers not reviewed by the FDA and located at unaccredited facilities. High-concentration oxygen sharply raises fire risk. |
| HBOT is not proven to cure cancer, Lyme, autism, or Alzheimer's | Strong | The FDA states these claims are unproven. A chamber cleared for one indication does not carry over to unproven wellness or disease claims. |
| Home 1.3 ATA use is lower-dose but far less studied | Limited | The incidence data above come from clinical HBOT at 2.0 to 2.8 ATA. There is no large safety trial of 1.3 ATA home chambers specifically. Lower pressure means lower per-session risk, but less studied is not zero risk. |
| A higher ATA is a better therapy | Anecdotal | No primary source supports this. Risk of oxygen toxicity rises with pressure, and higher pressure is only justified when the evidence supports benefit at that pressure for a specific condition. |
| A homemade zippered chamber with oxygen is safe | Anecdotal | The FDA warns that zippered bags cleared for altitude sickness are not cleared for oxygen use, and homemade HBOT devices carry a risk of fire and suffocation. The claim is contradicted by the FDA. |
The common complications, ranked
Order here is by how often something happens, not by how serious it is. Fire is last for a reason: it is rare, but it is the one that can kill.
Ear and sinus barotrauma: the one that actually happens
This is the most common complication and the most common reason people stop treatment. The FDA lists ear and sinus pain and middle-ear injuries, including eardrum rupture, as HBOT risks. Studies report middle-ear barotrauma in a wide range, roughly 13% to 43% of patients, and the vast majority is minor, mostly mild redness or discomfort rather than rupture. Congestion, a sinus infection, prior ear surgery, or trouble equalizing pressure all raise the odds. These are screening reasons, not reasons to avoid HBOT when a clinician has cleared you.
Temporary vision changes: reversible near-sightedness
A well-documented HBOT side effect is a temporary myopic shift, where distant objects look slightly blurry. Evanger 2004 measured a shift that was larger with hood delivery than with a mask and returned to baseline within about 6 to 10 weeks of finishing treatment. The same study found no significant change in lens transparency. It is temporary, but it is real, and divers or pilots should not make vision-critical decisions during a course of treatment.
Oxygen-toxicity seizure: rare, and tied to pressure
The dramatic-sounding one, and the one the marketing ignores. At clinical pressures, oxygen-toxicity seizures occur at roughly 1 in 2,100 to 1 in 3,400 treatments. The risk is sharply pressure-dependent: Heyboer 2014 measured zero seizures per 10,000 treatments at 2.0 ATA versus 51 per 10,000 at 2.8 ATA. People who seize often have other seizure-risk factors, such as certain medications, hypercapnia, or withdrawal. This is why screening matters and why a higher ATA is not automatically better.
Pulmonary effects: mostly subclinical
Oxygen toxicity can affect the lungs, but the picture at routine clinical doses is reassuring. Brenna 2023 followed patients through serial HBOT sessions and found no significant longitudinal change in FEV1, FVC, or FEF25-75, even among people with pre-existing respiratory disease. The FDA still lists lung collapse as a rare risk. This is observational data, not a randomized trial, so the honest grade is moderate.
Claustrophobia and anxiety: more common than the medical risks
The FDA and the complications literature treat confinement anxiety as a real consideration. A narrow fabric tube with a closed zipper is a lot to take for someone who does not like tight spaces. Severe claustrophobia can be a relative contraindication. This one tends to show up in reviews and return rates more than the medical literature, because it is a lived experience, not a billed complication.
Fire: rare, but the catastrophic one
Fire is the risk that can actually kill. The FDA has documented explosions and fires in chambers that were not reviewed by the FDA and located at unaccredited facilities. High-concentration oxygen makes ordinary materials far easier to ignite. The three FDA-cleared US home-chamber makers operate under a clearance, but unsupervised home use is not the same as a monitored clinical session. Never improvise oxygen connections, and follow the clothing, cleaning, and prohibited-item rules to the letter.
Who should not use a chamber
Screening is not a formality. There is one absolute stop and a list of relative ones, and they apply to a 1.3 ATA home chamber just as much as to a clinical chamber.
Absolute: untreated pneumothorax
The only absolute contraindication. Placing someone with an untreated pneumothorax under pressure can cause a life-threatening tension pneumothorax during ascent. This is not a judgment call; it is a screen that has to happen before any human use.
Relative: lungs, seizures, ears, and more
StatPearls lists relative contraindications including lung blebs or bullae, a history of seizures, claustrophobia, and current ear or sinus problems. Medications that lower the seizure threshold, such as some antibiotics and antidepressants, matter too. These are reasons a clinician should be in the loop, not reasons to self-sort into a chamber.
Glucose and medication review
Insulin-treated patients may need blood-glucose checks because the pressure and oxygen environment can interact with glucose control. Some medications, including bleomycin and doxorubicin, raise oxygen-toxicity risk. If you are on any regular medication, that is a conversation for the prescribing clinician before you buy a chamber.
Pressure, oxygen, and why 1.3 ATA is not clinical HBOT
A chamber's ATA rating tells you the ambient pressure. It does not tell you the oxygen partial pressure reaching the lungs. That depends on oxygen purity, mask fit, gas flow, leakage, and protocol. Clinical HBOT combines hard-sided pressure at 2.0 to 3.0 ATA with tightly controlled medical oxygen, trained staff, monitoring, and fire controls. A 1.3 ATA fabric chamber with filtered room air, sometimes with a concentrator mask, is not that.
The safety data here comes mostly from clinical HBOT at 2.0 to 2.8 ATA. At 1.3 ATA the oxygen-toxicity and barotrauma risk per session is lower, which is reassuring, but the home-chamber dose has not been studied at scale. Lower studied is not the same as zero risk.
For the full difference between mild home chambers and clinical HBOT, see our best home hyperbaric chambers guide and our $10,000 hyperbaric budget guide.
Fire and oxygen safety
Fire is the risk that can actually kill, and it is the one most marketing glosses over. The FDA has documented explosions and fires in chambers that were not reviewed by the FDA and located at unaccredited facilities. High-concentration oxygen makes materials far easier to ignite, which is why clothing rules, prohibited electronics, and oxygen-connection rules are not suggestions.
The FDA also warns against a specific trap: zippered bags cleared only for altitude sickness are not cleared for use with oxygen tanks or concentrators, yet people use them to build homemade HBOT devices. That combination carries a risk of fire and suffocation.
- • Verify the exact FDA clearance in the openFDA database before buying.
- • Never attach a concentrator to a chamber unless the cleared design and manufacturer instructions explicitly support it.
- • Keep a trained second adult outside the chamber who can depressurize it.
- • Follow the manufacturer's clothing, cleaning, and prohibited-item rules exactly.
- • Treat the phrase "FDA registered" as different from "FDA cleared." It is.
Who should not buy a home chamber
Not everyone should. Honest guidance beats a sale.
Anyone self-treating a diagnosis on a seller's protocol
If a clinician has not written a protocol that a 1.3 ATA chamber matches, a home chamber is a purchase looking for a reason. Get the written plan first.
Anyone chasing unproven claims like detox or cure-alls
The FDA says HBOT is not proven for cancer, Lyme, autism, or Alzheimer's. If the pitch is one of those, the marketing is ahead of the evidence.
Anyone with an untreated pneumothorax, lung blebs, a seizure history, or severe claustrophobia
These are screening stops. A clinician has to clear these before any human use, including at 1.3 ATA.
Anyone who wants the strongest therapy
A 1.3 ATA home chamber is not clinical HBOT. If the plan calls for clinical pressures and oxygen, a home chamber is not a cheaper substitute.
Claims that do not hold up
The marketing around hyperbaric use has run ahead of the science. These are the claims the evidence does not support.
It detoxes your body
No primary source supports hyperbaric exposure as a detox mechanism. Your liver and kidneys handle detoxification. Treat detox claims as marketing, not evidence.
It cures autism, Alzheimer's, Lyme, or cancer
The FDA explicitly says HBOT is not proven to cure these. A chamber cleared for wound healing does not carry over to these claims, and no reputable source says otherwise.
A higher ATA is always better
The opposite is closer to true. Oxygen-toxicity seizure risk rises with pressure, and higher pressure is only justified when the evidence shows benefit at that pressure for a specific condition. Shopping for the biggest ATA number is shopping for more risk, not more therapy.
A homemade chamber with a concentrator is a bargain
The FDA warns that altitude-sickness bags are not cleared for oxygen use, and homemade HBOT devices carry a risk of fire and suffocation. A cheaper rig is not a safe rig.
Frequently asked questions
Is a home hyperbaric chamber safe?
Clinical hyperbaric oxygen therapy is genuinely low-risk when used for FDA-cleared indications at a monitored facility, and serious complications are rare. A home chamber is a different situation: it runs at lower pressure (typically 1.3 ATA) with filtered room air, so the per-session risk is lower, but the setup is far less studied and is unsupervised. Safety depends on prescription screening, a verified FDA clearance, room and fire rules, and a trained second adult outside the chamber.
What are the side effects of hyperbaric oxygen therapy?
The FDA lists ear and sinus pain, middle-ear injuries including eardrum rupture, temporary vision changes, rare lung collapse, and the risk of fire as the potential risks of HBOT. Ear and sinus barotrauma is the most common complication and is usually minor. A temporary myopic (near-sighted) shift that resolves within about 10 weeks is also well documented. Oxygen-toxicity seizures are rare and more common at higher pressures.
Can a hyperbaric chamber cause a seizure?
Rarely. At clinical pressures, oxygen-toxicity seizures occur at roughly 1 in 2,100 to 1 in 3,400 treatments, and the risk rises sharply with higher pressure. Most people who seize in a chamber also have other seizure-risk factors such as certain medications, hypercapnia, or withdrawal. This is a screening reason, not a reason to avoid HBOT entirely when a clinician has cleared you.
Does hyperbaric oxygen therapy hurt your ears?
Ear and sinus pain is the most common HBOT complaint. Middle-ear barotrauma ranges from mild discomfort to eardrum rupture, and studies report it in roughly 13% to 43% of patients, with the vast majority being minor. Congestion, sinus infection, prior ear surgery, or trouble equalizing pressure should be reviewed by a clinician before a session.
Can HBOT damage your eyes or cause blurred vision?
HBOT commonly causes a temporary myopic shift, meaning distant objects look slightly blurry. The change is reversible and typically resolves within about 6 to 10 weeks of finishing treatment, and it tends to be more pronounced when oxygen is delivered by hood rather than by mask. No significant lens damage was found in the study we cite.
Can a hyperbaric chamber explode?
Fire is the catastrophic risk, and the FDA has documented explosions and fires in chambers that were not reviewed by the FDA and located at unaccredited facilities. High-concentration oxygen dramatically raises fire risk. The FDA also warns that zippered bags cleared only for altitude sickness are not cleared for use with oxygen, and homemade oxygen rigs pose fire and suffocation danger. Never improvise oxygen connections or ignore clothing, cleaning, and prohibited-item rules.
Who should not use a hyperbaric chamber?
An untreated pneumothorax is the only absolute contraindication, because changing pressure can cause a life-threatening tension pneumothorax during ascent. Relative contraindications include lung blebs or bullae, a history of seizures, claustrophobia, current ear or sinus problems, and some medications that lower the seizure threshold. A clinician must screen for these before any human use, including a 1.3 ATA home chamber.
Do I need a prescription for a home hyperbaric chamber?
Yes, for human medical use. US manufacturers of home chambers describe them as prescription Class II devices, and oxygen concentrators are also prescription devices. A seller willing to skip the prescription is a warning sign, not a convenience.
Is a 1.3 ATA home chamber as safe as clinical HBOT?
Not a comparable situation. Clinical HBOT at 2.0 to 2.8 ATA with medical oxygen is well studied in monitored facilities. A 1.3 ATA home chamber with filtered room air is lower-pressure and lower-dose, which lowers the per-session risk of oxygen toxicity and barotrauma, but there is no large safety trial of home chambers specifically, and sessions are unsupervised. Lower studied is not the same as zero risk.
Can you use a hyperbaric chamber with a homemade oxygen setup?
No. The FDA has not cleared zippered altitude-sickness bags for use with oxygen tanks or concentrators, and it is aware of people building homemade HBOT devices that pose a risk of fire and suffocation. Attach a concentrator to a chamber only if the cleared design and the manufacturer instructions explicitly support it.
Sources and methodology
This guide was assembled from official bodies and peer-reviewed sources. Every PMID was verified against the National Center for Biotechnology Information database, and the FDA fact sheet was fetched live, at the time of writing on August 21, 2026. The incidence data come from clinical HBOT at higher pressures; home 1.3 ATA use is far less studied. There is no large safety trial of 1.3 ATA home chambers specifically, and no single authoritative incidence for every complication across all protocols.
- FDA consumer fact sheet, archived 2023 for cleared uses, unproven claims, listed risks, and the warning against improvised oxygen connections.
- StatPearls: Hyperbaric Complications for barotrauma, oxygen toxicity, myopia, seizure, and claustrophobia.
- StatPearls: HBOT Contraindications for the absolute pneumothorax contraindication and relative ones.
- StatPearls: Oxygen Toxicity for CNS versus pulmonary toxicity mechanisms.
- Heyboer et al. 2014, Undersea Hyperb Med. Seizure incidence by treatment pressure. PMID 25558546.
- Hampson and Atik 2003, Undersea Hyperb Med. CNS oxygen toxicity during routine therapy. PMID 12964858.
- Seidel et al. 2013, Undersea Hyperb Med. Risk factors for oxygen-toxicity seizures. PMID 24377194.
- Heyboer et al. 2014, Undersea Hyperb Med. Middle ear barotrauma incidence. PMID 25558548.
- Edinguele et al. 2020, Undersea Hyperb Med. Five-year retrospective on 2,610 patients. PMID 32574438.
- Karahatay et al. 2008, Ear Nose Throat J. Middle ear barotrauma incidence. PMID 19105143.
- Bessereau et al. 2010, Undersea Hyperb Med. Middle-ear barotrauma after HBOT. PMID 20737927.
- Evanger et al. 2004, Acta Ophthalmol Scand. Ocular refractive changes. PMID 15291940.
- Brenna et al. 2023, PLoS One. Pulmonary function following HBOT. PMID 37256885.
This guide is a safety and buying decision aid, not medical advice. Talk to a hyperbaric physician before buying or using any chamber. Human medical use requires a prescription.